Usart, M., Rai, S., O'Connor, K., Kimmerlin, Q., Zaroogian, Z., Wereski, M., Xu, C., Masse, C., Hubbard, S., Levine, R., Kleppe, M., Škoda, R., Dunbar, A. (2025). AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs). Blood. https://doi.org/10.1182/blood-2025-1983